Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Juni 2015 09:17 ET | Quelle: XBiotech Inc.

XBiotech Added to Russell 2000 Index

AUSTIN, Texas, June 24, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc., (Nasdaq:XBIT), the developer of True HumanTM therapeutic antibodies, announced today that the Company has been added to the Russell 2000...
15. Juni 2015 11:45 ET | Quelle: XBiotech Inc.

CORRECTING and REPLACING -- XBiotech Announces Publication of Phase 2 Clinical Results for Its True Human(TM) Antibody MABp1 for Treating Acne Vulgaris

AUSTIN, Texas, June 15, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by XBiotech (Nasdaq:XBIT), please note that in the fifth paragraph the mean overall scores of...
15. Juni 2015 08:02 ET | Quelle: XBiotech Inc.

XBiotech Announces Publication of Phase 2 Clinical Results for Its True Human(TM) Antibody MABp1 for Treating Acne Vulgaris

AUSTIN, Texas, June 15, 2015 (GLOBE NEWSWIRE) -- XBiotech (Nasdaq:XBIT), the developer of True Human™ therapeutic antibodies, announces positive results from the Company's Phase 2 study of its...
08. Juni 2015 08:33 ET | Quelle: XBiotech Inc.

XBiotech Appoints Kelly R. Thornburg as Senior Vice President of Operations

AUSTIN, Texas, June 8, 2015 (GLOBE NEWSWIRE) -- XBiotech (Nasdaq:XBIT), the developer of True Human™ therapeutic antibodies, announced today that Kelly R. Thornburg has joined the company as...
28. Mai 2015 08:00 ET | Quelle: XBiotech Inc.

XBiotech Launching Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus Aureus

AUSTIN, Texas, May 28, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc. (Nasdaq:XBIT), a leading developer of next-generation True Human™ therapeutic antibodies, announced today that the Food and Drug...
26. Mai 2015 16:03 ET | Quelle: XBiotech Inc.

XBiotech Successfully Clones First Anti-Ebola Therapeutic Antibody Product Candidate

AUSTIN, Texas, May 26, 2015 (GLOBE NEWSWIRE) -- XBiotech (Nasdaq:XBIT), the developer of True Human™ therapeutic antibodies, announced today that it has successfully isolated and cloned an...
18. Mai 2015 08:02 ET | Quelle: XBiotech Inc.

XBiotech Secures Approval From Data Safety Monitoring Board to Continue Phase 3 Registration Study in Europe for Its Novel Cancer Immunotherapy

AUSTIN, Texas, May 18, 2015 (GLOBE NEWSWIRE) -- XBiotech (Nasdaq:XBIT), developer of Xilonix anti-cancer therapy for the treatment of colorectal cancer, announced today that the Data Safety Monitoring...
29. April 2015 08:00 ET | Quelle: XBiotech Inc.

XBiotech Enrolls First Patient Under Revised Protocol for U.S. Phase 3 Registration Study Using Xilonix(TM) for Treatment of Metastatic Colorectal Cancer

AUSTIN, Texas, April 29, 2015 (GLOBE NEWSWIRE) -- XBiotech (Nasdaq:XBIT), a leading developer of next-generation True Human™ therapeutic antibodies, announced today that it has enrolled the...
17. April 2015 14:13 ET | Quelle: XBiotech Inc.

XBiotech Closes Initial Public Offering

AUSTIN, Texas, April 17, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc. (Nasdaq:XBIT), a leading developer of next-generation therapeutic antibodies, announced today the closing of its initial public offering...
14. April 2015 17:25 ET | Quelle: XBiotech Inc.

XBiotech Announces Pricing of Initial Public Offering

AUSTIN, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc., a leading developer of next-generation therapeutic antibodies, announced today the pricing of its initial public offering of 4,000,000...